The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Androgen Deprivation Therapy in Prostate Cancer and Metabolic Risk for Atherosclerosis
Open accessAbstract
Context: Prostate cancer (PCa) is the most common cancer in men. Androgen-deprivation therapy (ADT) is generally employed in the treatment of locally advanced and metastatic PCa. Although its use as an adjuvant therapy has resulted in improved survival in some patients, ADT has negative consequences. Complications like osteoporosis, sexual dysfunction, gynecomastia, and adverse body composition are well known. Recently, metabolic complications like insulin resistance, diabetes, dyslipidemia, and metabolic syndrome have emerged, which may be responsible for the increased cardiovascular mortality in this population. Evidence Acquisition: A MEDLINE search was conducted for articles published over the last 20 yr based on the key words androgen deprivation therapy AND insulin resistance, hyperglycemia, diabetes, dyslipidemia, metabolic syndrome, and cardiovascular disease. Relevant studies in non-PCa populations evaluating the association between testosterone and metabolism were also reviewed and briefly mentioned where relevant. Evidence Synthesis: Prospective studies evaluating early (3–6 months) metabolic changes of ADT show development of hyperinsulinemia; however, glucose levels remain normal. Cross-sectional studies of men undergoing long-term (≥12 months) ADT reveal higher prevalence of diabetes and metabolic syndrome compared with controls. Furthermore, men undergoing ADT also experience higher cardiovascular mortality. Conclusion: Long-term prospective studies of ADT are needed to determine the timing of onset of these metabolic complications and to investigate the mechanism behind them. In the meantime, we recommend baseline and serial screening for fasting glucose, lipids, and other cardiovascular risk factors in men receiving ADT. Glucose tolerance tests and cardiac evaluation may be required in selected cases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssönen, K., Tuomainen, T.-P., Valkonen, V.-P., Salonen, R., & Salonen, J. T. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1036 · Cited by 920
Malkin, C. J., Pugh, P. J., Jones, R. D., Kapoor, D., Channer, K. S., & Jones, T. H. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031069 · Cited by 731
Changes in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
Saigal, C. S., Gore, J. L., Krupski, T. L., Hanley, J., Schonlau, M., & Litwin, M. S. (2007) · Cancer · doi:10.1002/cncr.22933 · Cited by 542
D'Amico, A. V., Denham, J. W., Crook, J., Chen, M.-H., Goldhaber, S. Z., Lamb, D. S., Joseph, D., Tai, K.-H., Malone, S., Ludgate, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3369 · Cited by 501
Insulin sensitivity during combined androgen blockade for prostate cancer
Smith, M. R., Lee, H., & Nathan, D. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2507 · Cited by 493
Haffner, S. M., Shaten, J., Stem, M. P., Smith, G. D., Kuller, L., & MRFIT Research Group (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008832 · Cited by 320
Haffner, S. M., Valdez, R. A., Mykkänen, L., Stern, M. P., & Katz, M. S. (1994) · Metabolism · doi:10.1016/0026-0495(94)90202-x · Cited by 226 · cited 1×
“Epidemiological studies have shown that low testosterone levels predict the development of insulin resistance, type 2 diabetes, and metabolic syndrome in men (12, 21 , 22).”
Background
Cited by
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O., Eberg, M., Benayoun, S., Aprikian, A., Batist, G., Suissa, S., & Azoulay, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 659
Testosterone: a metabolic hormone in health and disease
Kelly, D. M., & Jones, T. H. (2013) · Journal of Endocrinology · doi:10.1530/joe-12-0455 · Cited by 577
The effects of opioids and opioid analogs on animal and human endocrine systems
Vuong, C., Van Uum, S. H. M., O'Dell, L. E., Lutfy, K., & Friedman, T. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0009 · Cited by 564
“In males, chronic hypogonadism, either spontaneous or induced by GnRH agonists, is associated with increased insulin resistance and risk for diabetes mellitus, but not frank hyperglycemia (398), and testosterone replacement may improve insulin resistance (399).”
Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer
Saylor, P. J., & Smith, M. R. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.01.047 · Cited by 349
Brand, J. S., van der Tweel, I., Grobbee, D. E., Emmelot-Vonk, M. H., & van der Schouw, Y. T. (2011) · International Journal of Epidemiology · doi:10.1093/ije/dyq158 · Cited by 334
Basaria, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61126-5 · Cited by 328
Self-citationReview of major adverse effects of androgen‐deprivation therapy in men with prostate cancer
Taylor, L. G., Canfield, S. E., & Du, X. L. (2009) · Cancer · doi:10.1002/cncr.24283 · Cited by 324
The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes and Insulin Resistance
Traish, A. M., Saad, F., & Guay, A. (2009) · Journal of Andrology · doi:10.2164/jandrol.108.005751 · Cited by 266
Endocrine Aspects of Male Sexual Dysfunctions
Buvat, J., Maggi, M., Gooren, L., Guay, A. T., Kaufman, J., Morgentaler, A., Schulman, C., Tan, H. M., Torres, L. O., Yassin, A., et al. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01780.x · Cited by 221
Yeap, B. B., Chubb, S. A. P., Hyde, Z., Jamrozik, K., Hankey, G. J., Flicker, L., & Norman, P. E. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0348 · Cited by 128
Management of side effects of androgen deprivation therapy
Grossmann, M., & Zajac, J. D. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.05.004 · Cited by 69
Ethical and medical considerations of androgen deprivation treatment of sex offenders
Gooren, L. J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1540 · Cited by 39
Short-Term Estrogen Withdrawal Increases Adiposity in Healthy Men
Chao, J., Rubinow, K. B., Kratz, M., Amory, J. K., Matsumoto, A. M., & Page, S. T. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1482 · Cited by 25
Correlation of sex hormone and androgen receptor with diabetes mellitus in elderly men
Cao, J., Li, J., Hao, W., Li, X., Wang, H., Liu, L., Zhu, B., & Guo, Z. (2011) · The Aging Male · doi:10.3109/13685538.2011.575479 · Cited by 21
“found that prostate cancer patients who received 3–6 months of testosterone therapy after castration were prone to early metabolic changes and hyperinsulinemia, and those who received more than 12 months of therapy were prone to a higher incidence of metabolic syndrome [18].”
BackgroundRubinow, K., Houston, B., Wang, S., Goodspeed, L., Ogimoto, K., Morton, G., McCarty, C., Braun, R., & Page, S. (2018) · Asian Journal of Andrology · doi:10.4103/aja.aja_54_17 · Cited by 7
Metadata
- Authors
- Shahani, S., Braga-Basaria, M., & Basaria, S.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-06-01
- Volume
- 93
- Issue
- 6
- Pages
- 2042-2049
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2153275681
- Cited by
- 185
- References
- 10
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.